---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035391"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:32:25.841203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva Q3 net loss $8.4M; 108 patients complete 1-year OLE trial for brilaroxazine

## Summary
- Net loss of $8.4M ($0.25/sh) for Q3 2024 vs $11.3M ($0.48/sh) in Q3 2023 (restated).
- Cash totaled $5.6M as of Sep 30, 2024, down from $23.4M at Dec 31, 2023.
- 108 patients have completed 1 year of treatment in brilaroxazine OLE trial; topline data expected December 2024.
- NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026; RECOVER-2 start expected Q1 2025 pending financing.

## SEC filing metadata
- accession: 0001437749-24-035391
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/0001437749-24-035391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924035391/rvph20241107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035391
- JSON: https://secwatch.observer/filing/0001437749-24-035391.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.